Liang Cao1, Luke V Selby2, Xiang Hu1, Yi Zhang1, Yelena Y Janjigian3, Laura Tang4, Daniel G Coit2, Murray F Brennan2, Vivian E Strong2. 1. Department of General Surgery, The First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, China. 2. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York City, New York. 3. Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York City, New York. 4. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York City, New York.
Abstract
INTRODUCTION: Recurrence patterns after curative intent gastrectomy for T1-2N0 gastric adenocarcinoma are poorly defined. We sought to assess timing, patterns, and risk factors for recurrence in patients treated at two high-volume gastric cancer centers in the United States and China. METHODS: Between 1995 and 2011, 1,058 patients underwent curative intent gastrectomy. Recurrences were classified as locoregional, distant, or peritoneal. Univariate and multivariate analyses were performed to identify risk factors for recurrence. RESULTS: Overall, 7% (76) of our 1,058 patients from the United States (n = 414) and China (n = 644) recurred. Liver (43%) was the most common site of recurrence in both countries (US: 24%, China: 52%), followed by peritoneum (16%), lymph nodes (10%), and anastomosis (8%). Median time to recurrence was 23 months (US: 30 months, China: 23 months), which decreased with increasing T-stage (T1a: 27 months, T1b: 24 months, T2: 22 months). Tumor size (P = 0.001), depth of invasion (P = 0.010), histological type (P = 0.022) and lymphovascular invasion (P = 0.001) were independently associated with recurrence. CONCLUSION: Patients infrequently recur following curative intent gastrectomy for T1-2N0 gastric adenocarcinoma. Almost all recurrences occur between six months and 3 years post-operatively, most frequently in distant anatomic locations; selective followup during this time period is recommended. J. Surg. Oncol. 2016;113:745-749.
INTRODUCTION: Recurrence patterns after curative intent gastrectomy for T1-2N0 gastric adenocarcinoma are poorly defined. We sought to assess timing, patterns, and risk factors for recurrence in patients treated at two high-volume gastric cancer centers in the United States and China. METHODS: Between 1995 and 2011, 1,058 patients underwent curative intent gastrectomy. Recurrences were classified as locoregional, distant, or peritoneal. Univariate and multivariate analyses were performed to identify risk factors for recurrence. RESULTS: Overall, 7% (76) of our 1,058 patients from the United States (n = 414) and China (n = 644) recurred. Liver (43%) was the most common site of recurrence in both countries (US: 24%, China: 52%), followed by peritoneum (16%), lymph nodes (10%), and anastomosis (8%). Median time to recurrence was 23 months (US: 30 months, China: 23 months), which decreased with increasing T-stage (T1a: 27 months, T1b: 24 months, T2: 22 months). Tumor size (P = 0.001), depth of invasion (P = 0.010), histological type (P = 0.022) and lymphovascular invasion (P = 0.001) were independently associated with recurrence. CONCLUSION:Patients infrequently recur following curative intent gastrectomy for T1-2N0 gastric adenocarcinoma. Almost all recurrences occur between six months and 3 years post-operatively, most frequently in distant anatomic locations; selective followup during this time period is recommended. J. Surg. Oncol. 2016;113:745-749.
Authors: J H Kim; H S Kim; W Y Seo; C M Nam; K Y Kim; H C Jeung; J F Lai; H C Chung; S H Noh; S Y Rha Journal: Ann Oncol Date: 2011-05-12 Impact factor: 32.976
Authors: Michael D'Angelica; Mithat Gonen; Murray F Brennan; Alan D Turnbull; Manjit Bains; Martin S Karpeh Journal: Ann Surg Date: 2004-11 Impact factor: 12.969
Authors: Bang Wool Eom; Hongman Yoon; Keun Won Ryu; Jun Ho Lee; Soo Jeong Cho; Jong Yeul Lee; Chan Gyoo Kim; Il Ju Choi; Jong Seok Lee; Myung Cherl Kook; Sook Ryun Park; Byung-Ho Nam; Young-Woo Kim Journal: Dig Surg Date: 2010-11-10 Impact factor: 2.588
Authors: Ji Fu Lai; Sungsoo Kim; Kiyeol Kim; Chen Li; Sung Jin Oh; Woo Jin Hyung; Sun Young Rha; Hyun Cheol Chung; Seung Ho Choi; Lin Bo Wang; Sung Hoon Noh Journal: Ann Surg Oncol Date: 2009-05-12 Impact factor: 5.344
Authors: Jaffer A Ajani; David J Bentrem; Stephen Besh; Thomas A D'Amico; Prajnan Das; Crystal Denlinger; Marwan G Fakih; Charles S Fuchs; Hans Gerdes; Robert E Glasgow; James A Hayman; Wayne L Hofstetter; David H Ilson; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; A Craig Lockhart; Kenneth Meredith; Mary F Mulcahy; Mark B Orringer; James A Posey; Aaron R Sasson; Walter J Scott; Vivian E Strong; Thomas K Varghese; Graham Warren; Mary Kay Washington; Christopher Willett; Cameron D Wright; Nicole R McMillian; Hema Sundar Journal: J Natl Compr Canc Netw Date: 2013-05-01 Impact factor: 11.908
Authors: J Datta; E M Da Silva; C Kandoth; T Song; A E Russo; J M Hernandez; B S Taylor; Y Y Janjigian; L H Tang; D B Solit; V E Strong Journal: Br J Surg Date: 2019-11-25 Impact factor: 6.939